Roche Pharma AG (Germany)

89.8k citations
2.2k papers ·

Impact in

  • Oncology top 5%
    • CAR-T cell therapy research
    • Cancer-related Molecular Pathways
    • Cancer Immunotherapy and Biomarkers
  • Immunology top 10%
    • Immune cells in cancer

Papers in

Roche Pharma AG (Germany)

1.9k papers receiving 75.7k citations

Peers

Roche Pharma AG (Germany)
Comparison fields: 5 of 230
  • Oncology 17.4k
  • Immunology 11.1k
  • Radiology, Nuclear Medicine and Imaging 10.6k
  • Molecular Biology 31.3k
  • Cancer Research 5.2k
Replace Merck KGaA, Darmstadt (Germany) with:
Merck KGaA, Darmstadt (Germany) Germany
Ripamonti Italy
Institut pour l'avancée des biosciences France
Deutsches Diabetes-Zentrum e.V. Germany
MultiMedica Italy
Centre Georges François Leclerc France
Institute of Oncology Research Switzerland
Ospedale San Luigi Gonzaga Italy
Centre Antoine Lacassagne France
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino Italy
Roche Pharma AG (Germany) relative to Merck KGaA, Darmstadt (Germany) Germany Merck KGaA, Darmstadt (Germany)'s profile →
Citations per field
00.5×1.5×
Merck KGaA, Darmstadt (Germany) · 1×
Citations per year

Countries citing scholars working at Roche Pharma AG (Germany)

Since Specialization
Citations

This map shows the geographic impact of research produced by authors working at Roche Pharma AG (Germany). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Roche Pharma AG (Germany) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roche Pharma AG (Germany) more than expected).

Fields of papers published by authors at Roche Pharma AG (Germany)

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers affiliated with Roche Pharma AG (Germany) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Roche Pharma AG (Germany) at the time of their publication.

About Roche Pharma AG (Germany)

In recent decades, authors affiliated with Roche Pharma AG (Germany) have published 2.2k papers, which have received a total of 89.8k indexed citations . Scholars at this organization have produced 371 papers in Radiology, Nuclear Medicine and Imaging, 372 papers in Oncology, 809 papers in Molecular Biology, 240 papers in Immunology and 110 papers in Cancer Research on the topics of Monoclonal and Polyclonal Antibodies Research (319 papers), Protein purification and stability (187 papers), Glycosylation and Glycoproteins Research (123 papers), Viral Infectious Diseases and Gene Expression in Insects (121 papers), CAR-T cell therapy research (80 papers), Biosimilars and Bioanalytical Methods (74 papers), Alzheimer's disease research and treatments (67 papers) and HER2/EGFR in Cancer Research (63 papers). Their work is cited by papers focused on Oncology (17.4k citations), Immunology (11.1k citations), Radiology, Nuclear Medicine and Imaging (10.6k citations), Molecular Biology (31.3k citations) and Cancer Research (5.2k citations). Authors at Roche Pharma AG (Germany) collaborate with scholars in Germany, Switzerland and United States and have published in prestigious journals including Alzheimer s & Dementia, Clinical Chemistry and Laboratory Medicine (CCLM), mAbs, PLoS ONE and Blood. Some of Roche Pharma AG (Germany)'s most productive authors include Christian Georg Klein, Ulrich H. Weidle, Ulrich Brinkmann, Manfred Kubbies, Roland E. Kontermann, Carola Hermine Ries, Bradford J. Graves, Lyubomir T. Vassilev, Wolfgang H. Petrich and Wilhelm Tischer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore institutions with similar magnitude of impact